NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required)
ID: 352066Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/352066

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-100.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity through the NIAID Clinical Trial Implementation Cooperative Agreement (U01), aimed at supporting investigator-initiated, high-risk clinical trials focused on infectious, immunologic, and allergic diseases. This initiative encourages applications that promote the understanding of human diseases and the development of future therapeutic modalities, with a requirement that only one clinical trial may be proposed per application. The cooperative agreement emphasizes significant NIH involvement in project activities, ensuring alignment with NIAID's research goals while maintaining primary responsibility with the awardee. Interested applicants, including various educational institutions and organizations, must adhere to strict application guidelines, including the submission of a Data Management and Sharing Plan, with deadlines for submission starting on April 12, 2024. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link to the full announcement.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-100-Full-Announcement.html
    PAR-24-100.html
    The NIAID Clinical Trial Implementation Cooperative Agreement (U01) offers funding for investigator-initiated, high-risk clinical trials focusing on infectious, immunologic, and allergic diseases. It aims to enhance understanding of human diseases and develop therapeutic approaches. Applicants may propose only one clinical trial per application, with submission deadlines starting on April 12, 2024. PIs and organizations must comply with strict application guidelines, including the requirement of a Data Management and Sharing Plan. The review process evaluates the significance, innovation, and approach of the proposed trials, with an emphasis on collaboration with NIH staff throughout the project. Eligible applicants include various educational institutions, nonprofits, and for-profit entities. The cooperative agreement fosters significant NIH involvement in project activities, ensuring that research aligns with NIAID's goals while maintaining the primary responsibility with the awardee. The total funding is contingent upon NIH appropriations, with budgets reflecting the actual needs of the project. This initiative underscores the NIH's commitment to advancing medical knowledge through high-risk clinical trials addressing pressing health issues.
    Similar Opportunities
    NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (FON PAR-24-099) aimed at small business concerns proposing investigator-initiated clinical trials that align with the NIAID's research mission. This program supports hypothesis-driven and milestone-driven clinical trials, particularly those classified as high-risk, which may involve unique interventions or the use of licensed products for unapproved indications. The initiative underscores the government's commitment to advancing innovative clinical research to address significant healthcare challenges, with funding of up to $1 million annually available for meritorious applications. Interested applicants must adhere to strict guidelines and submit their applications by the various deadlines, with the first due date on April 12, 2024, and the final deadline on January 13, 2027. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01), aimed at supporting investigator-initiated, high-risk clinical trials that involve multiple clinical centers. Applicants must propose hypothesis-driven studies that focus on diseases relevant to the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), with an emphasis on enhancing diverse perspectives in research. This funding opportunity is crucial for advancing therapeutic studies that can significantly improve clinical practices and public health outcomes. Interested applicants should note that the application period opens on January 5, 2024, with a closing date of November 5, 2026, and are encouraged to consult with NIDDK staff prior to submission. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for the NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3), aimed at supporting interventional clinical trials focused on rheumatic, musculoskeletal, and skin diseases. This initiative encompasses a two-phase approach, where the UG3 phase involves trial preparation and the UH3 phase focuses on trial execution, contingent upon meeting specific milestones. The program emphasizes the importance of developing clinical protocols, obtaining IRB approval, and securing necessary resources, while also promoting health equity by engaging individuals with lived experience in the research process. Interested applicants can apply for funding up to $250,000 for the UG3 phase, with a closing date for submissions set for March 4, 2027. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-208.html.
    NIAID Clinical Trial Planning Grant (R34 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Allergy and Infectious Diseases (NIAID), has announced a funding opportunity for the Clinical Trial Planning Grant (R34), aimed at supporting the planning and preparation necessary for investigator-initiated clinical trials. This grant encourages applications that focus on high-priority research aligned with NIAID's mission, providing funding of up to $150,000 for activities such as protocol development, study team establishment, and regulatory approvals. The opportunity is open to a diverse range of eligible applicants, including educational institutions, nonprofits, and governmental entities, with applications evaluated based on significance, innovation, and the research environment. Interested applicants should note that the application deadline is May 13, 2026, and can find more information at the provided NIH grants link or by contacting NIH Grants Information at grantsinfo@nih.gov.
    NIAID Resource-Related Research Projects (R24 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Allergy and Infectious Diseases (NIAID), is offering a funding opportunity for investigator-initiated Resource-Related Research Projects (R24), specifically excluding clinical trials. This initiative aims to enhance existing high-priority research by supporting resources that provide critical data, materials, tools, or services beneficial to the scientific community, particularly in areas related to immunology and infectious diseases. Eligible applicants include a diverse range of institutions, such as higher education and nonprofit organizations, with proposals due by January 7, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-23-065.html.
    NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), is offering a funding opportunity for high-risk multi-center clinical study implementation planning via Cooperative Agreements (U34). This initiative aims to support the early peer review of proposed clinical studies, assess study designs, and develop essential documentation, including operational manuals, focusing on diseases relevant to NIDDK's mission. The program emphasizes health equity and inclusivity, requiring a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. Interested applicants can apply for up to $225,000 per year for a maximum of two years, with the application submission period opening on September 9, 2024, and the closing date set for June 10, 2027. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01), aimed at supporting high-risk observational studies related to diabetes, digestive, kidney, and metabolic diseases. Applicants must complete all planning activities prior to submission, as these cannot be included in the U01 application, and a Plan for Enhancing Diverse Perspectives (PEDP) is mandatory for consideration. This funding opportunity is crucial for advancing clinical research and addressing health disparities, particularly by encouraging collaboration with underrepresented communities. Interested applicants should note that the application deadline is February 5, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NINDS Exploratory Clinical Trials (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Neurological Disorders and Stroke (NINDS), is offering a funding opportunity for investigator-initiated exploratory clinical trials under the UG3/UH3 mechanism. This initiative aims to support Phase 1 and Phase 2 clinical trials that address critical questions related to neurological disorders, focusing on studies involving drugs, biologics, devices, and early interventions. The program emphasizes rigorous research design and encourages diverse and innovative research teams, with grants potentially spanning up to five years, beginning with a planning phase before transitioning to execution. Interested applicants can find more information and application details at the provided link, with a submission deadline of March 10, 2025, and no cost-sharing or matching requirement.
    NIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Allergy and Infectious Diseases (NIAID), is inviting applications for the Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed) grant. This funding opportunity aims to support multi-project research initiatives that focus on infectious, immunologic, and allergic diseases, requiring each application to include at least two synergistic research projects and an administrative core, all centered around a common theme. The initiative is crucial for advancing research in areas such as the biology and pathogenesis of infectious microbes, immune system mechanisms, and the development of vaccines and therapeutics. Interested applicants must submit their proposals electronically via Grants.gov by September 7, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. The funding amount is not limited but should reflect the actual needs of the proposed projects.
    NIDCR Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a Funding Opportunity Announcement (FOA) for the NIDCR Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3), aimed at supporting research applications focused on planning and executing clinical trials related to dental, oral, and craniofacial health. This funding opportunity is structured in two phases: an initial one-year planning phase (UG3) followed by a potential five-year implementation phase (UH3), contingent upon meeting specific scientific milestones and feasibility requirements. The initiative seeks to expedite the development of evidence-based approaches to improve health outcomes in dentistry, emphasizing rigorous adherence to ethical and regulatory standards throughout the trial process. Interested applicants, including various higher education institutions and nonprofit organizations, must submit their applications by January 8, 2025, and can find additional information at the NIH grants website or contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for assistance.